Details for Patent: 8,158,601

Which drugs does patent 8,158,601 protect, and when does it expire?

Patent 8,158,601 protects ONPATTRO and is included in one NDA.

This patent has seventy patent family members in twenty-three countries.

Summary for Patent: 8,158,601

Title:	Lipid formulation
Abstract:	The invention features a cationic lipid of formula I, ##STR00001## an improved lipid formulation comprising a cationic lipid of formula I and corresponding methods of use. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
Inventor(s):	Chen; Jianxin (Cambridge, MA), Ansell; Steven (Cambridge, MA), Akinc; Akin (Cambridge, MA), Dorkin; Joseph Robert (Cambridge, MA), Qin; Xiaojun (Cambridge, MA), Cantley; William (Cambridge, MA), Manoharan; Muthiah (Cambridge, MA), Rajeev; Kallanthottathil G. (Cambridge, MA), Narayanannair; Jayaprakash K. (Cambridge, MA), Jayaraman; Muthusamy (Cambridge, MA)
Assignee:	Alnylam Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	12/813,448
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,158,601
Patent Claim Types: see list of patent claims	Use; Formulation; Compound; Delivery;

Drugs Protected by US Patent 8,158,601

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alnylam Pharms Inc	ONPATTRO	patisiran sodium	SOLUTION;INTRAVENOUS	210922-001	Aug 10, 2018		RX	Yes	Yes			Y			TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS

International Family Members for US Patent 8,158,601

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010259984
Australia	2017202702
Australia	2019204984
Australia	2021201228
Canada	2764609